OCUL
Ocular Therapeutix, Inc.
NASDAQ · USHealthcareBiotechnology
$8.71-2.90%
Price as of Jul 20, 2026
OCUL growth
Ocular Therapeutix, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -12.8%
- EBITDA
- -55.5%
- EBIT
- -46.7%
- EPS
- -27.0%
- Free cash flow
- -62.3%
- Operating cash flow
- -55.5%
Forward estimates
- Revenue
- +33.4%
- EBITDA
- +80.0%
- EPS
- +11.5%
Three-year CAGR
- Revenue
- +0.2%
- EBITDA
- -41.8%
- EBIT
- -57.2%
- Net income
- -37.4%
- EPS
- -16.4%
- Free cash flow
- -59.5%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.